Who we are
ASIT biotech is a clinical stage biopharmaceutical company focused on the development and future commercialization of effective immunotherapy drugs.
The ASIT biotech platform allows the production, characterisation and quality control of truly new active ingredients consisting of highly purified natural allergen fragments, in an optimal size selection. The ASIT biotech technology platform is applicable to a broad range of allergens.
Discover our products
Our products are designed to improve patient acceptance and compliance leading to higher real-life effectiveness. The lead product gp-ASIT+TM for grass pollen rhinitis is currently in phase III. The second product candidate hdm-ASIT+TM targets the house dust mite rhinitis, its preclinical development is completed. Two other ASIT+TM product candidates are currently in discovery phase.
- ASIT biotech to publish its annual financial report on Tuesday, April 25, 2017 20-Apr-2017
- ASIT biotech presents its 2016 annual results and recent updates in clinical developments 11-Apr-2017
- ASIT biotech announces that it has achieved the primary endpoint of the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis 04-Apr-2017
- ASIT biotech announces the appointment of Gerd Zettlmeissl as the Company’s new Chairman of the Board 20-Mar-2017
- ASIT biotech reports positive results in its Phase III clinical trial with gp-ASIT+™ for grass pollen induced allergic rhinitis 28-Feb-2017